145 related articles for article (PubMed ID: 2434310)
1. The Bereitschaftspotential, L-DOPA and Parkinson's disease.
Dick JP; Cantello R; Buruma O; Gioux M; Benecke R; Day BL; Rothwell JC; Thompson PD; Marsden CD
Electroencephalogr Clin Neurophysiol; 1987 Mar; 66(3):263-74. PubMed ID: 2434310
[TBL] [Abstract][Full Text] [Related]
2. [Changes in movement-related cortical potentials in Parkinson's patients before and after treatment with levodopa].
Feve AP; Bathien N; Rondot P
Neurophysiol Clin; 1991 May; 21(2):105-19. PubMed ID: 1921938
[TBL] [Abstract][Full Text] [Related]
3. Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects.
Jahanshahi M; Jenkins IH; Brown RG; Marsden CD; Passingham RE; Brooks DJ
Brain; 1995 Aug; 118 ( Pt 4)():913-33. PubMed ID: 7655888
[TBL] [Abstract][Full Text] [Related]
4. Chronic administration of L-dopa affects the movement-related cortical potentials of patients with Parkinson's disease.
Feve AP; Bathien N; Rondot P
Clin Neuropharmacol; 1992 Apr; 15(2):100-8. PubMed ID: 1591735
[TBL] [Abstract][Full Text] [Related]
5. L-dopa effects on preprogramming and control activity in a skilled motor act in Parkinson's disease.
Fattapposta F; Pierelli F; My F; Mostarda M; Del Monte S; Parisi L; Serrao M; Morocutti A; Amabile G
Clin Neurophysiol; 2002 Feb; 113(2):243-53. PubMed ID: 11856629
[TBL] [Abstract][Full Text] [Related]
6. Contingent negative variation and movement-related cortical potentials in parkinsonism.
Oishi M; Mochizuki Y; Du C; Takasu T
Electroencephalogr Clin Neurophysiol; 1995 Nov; 95(5):346-9. PubMed ID: 7489663
[TBL] [Abstract][Full Text] [Related]
7. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
[TBL] [Abstract][Full Text] [Related]
8. The Bereitschaftspotential is abnormal in Parkinson's disease.
Dick JP; Rothwell JC; Day BL; Cantello R; Buruma O; Gioux M; Benecke R; Berardelli A; Thompson PD; Marsden CD
Brain; 1989 Feb; 112 ( Pt 1)():233-44. PubMed ID: 2917279
[TBL] [Abstract][Full Text] [Related]
9. Psychophysiological approach in Parkinson's disease: L-dopa effects on preprogramming and control activity.
Fattapposta F; Pierelli F; My F; Mostarda M; Del Monte S; Parisi L; Serrao M; Locuratolo N; Amabile G
Neurol Sci; 2002 Sep; 23 Suppl 2():S73-4. PubMed ID: 12548350
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
Paul R; Borah A
Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
[TBL] [Abstract][Full Text] [Related]
11. Acute effects of L-dopa on event-related desynchronization in Parkinson's disease.
Magnani G; Cursi M; Leocani L; Volonté MA; Comi G
Neurol Sci; 2002 Sep; 23(3):91-7. PubMed ID: 12391492
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
[TBL] [Abstract][Full Text] [Related]
13. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
14. Managing Parkinson's disease with continuous dopaminergic stimulation.
Wolters E; Lees AJ; Volkmann J; van Laar T; Hovestadt A
CNS Spectr; 2008 Apr; 13(4 Suppl 7):1-14; quiz 15-6. PubMed ID: 18408654
[TBL] [Abstract][Full Text] [Related]
15. Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Geng X; Wang X; Xie J; Zhang X; Wang X; Hou Y; Lei C; Li M; Han H; Yao X; Zhang Q; Wang M
Behav Brain Res; 2016 Dec; 315():1-9. PubMed ID: 27515286
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
17. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
[TBL] [Abstract][Full Text] [Related]
18. Subthalamic stimulation and levodopa modulate cortical reactivity in Parkinson's patients.
Casula EP; Stampanoni Bassi M; Pellicciari MC; Ponzo V; Veniero D; Peppe A; Brusa L; Stanzione P; Caltagirone C; Stefani A; Koch G
Parkinsonism Relat Disord; 2017 Jan; 34():31-37. PubMed ID: 27771287
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.
Cools R; Stefanova E; Barker RA; Robbins TW; Owen AM
Brain; 2002 Mar; 125(Pt 3):584-94. PubMed ID: 11872615
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Bereitschaftspotential and reaction time measurements in patients with Parkinson's disease. Measuring the impaired supplementary motor area function?
Filipović SR; Covicković-Sternić N; Radović VM; Dragasević N; Stojanović-Svetel M; Kostić VS
J Neurol Sci; 1997 Apr; 147(2):177-83. PubMed ID: 9106125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
